Treatment of AIDS Vacuolar Myelopathy with Methionine - Article
Clinical Trial: Treatment of AIDS Vacuolar Myelopathy with Methionine
This study has been completed.
The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.
|Condition||Treatment or Intervention||Phase|
AIDS vacuolar myelopathy
| Drug: methionine ||Phase III |
MedlinePlus related topics: AIDS; Bone Marrow Diseases; Spinal Cord Diseases
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control
Expected Total Enrollment: 56
Myelopathy is usually a late complication of AIDS, and until recently its symptoms were rarely recognized, masked by the general state of disability or the presence of other neurological complications. With prolonged survival and improved quality of life of HIV-infected patients, myelopathy is increasingly becoming a common source of disability. The cause of AIDS-myelopathy is unknown, but it is probably an indirect effect of the long-term presence of the HIV virus in the nervous system rather than the result of a direct infection. The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.
Ages Eligible for Study: 18 Years - 80 Years, Genders Eligible for Study: Both
Beth Israel Medical Center, New York, New York, 10003, United States
Alessandro Di Rocco, MD, Principal Investigator
Record last reviewed: March 2004
Last Updated: October 13, 2004
Record first received: March 28, 2002
ClinicalTrials.gov Identifier: NCT00032695
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Cache Date: April 9, 2005